Ralliant Corporation (NYSE:RAL) Plans $0.05 Quarterly Dividend

Key Points

• Ralliant (NYSE: RAL) declared a quarterly dividend of $0.05 per share, with shareholders of record on June 8, an ex-dividend date of June 8, and payment on June 23, implying an annualized yield of about 0.4%.
• The company reported Q4 EPS of $0.69 (beating estimates of $0.67) on revenue of $554.6M (up 1.2% YoY); Ralliant has a market cap of $5.18B, a P/E of 23.63, and analysts forecast ~2.37 EPS for the current fiscal year, while it markets point-of-care cell therapy systems using adipose-derived SVF cells.

Ralliant Corporation (NYSE:RAL - Get Free Report) declared a quarterly dividend on Thursday, May 7th. Shareholders of record on Monday, June 8th will be paid a dividend of 0.05 per share on Tuesday, June 23rd. This represents a c) dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, June 8th.

Ralliant Stock Performance

Shares of NYSE RAL opened at $46.32 on Friday. The stock has a fifty day moving average price of $44.26 and a two-hundred day moving average price of $47.00. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.58 and a current ratio of 0.84. The firm has a market cap of $5.18 billion and a P/E ratio of 23.63. Ralliant has a 1 year low of $37.27 and a 1 year high of $57.02.

Ralliant (NYSE:RAL - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.02. The firm had revenue of $554.60 million for the quarter, compared to the consensus estimate of $543.04 million. The firm's quarterly revenue was up 1.2% on a year-over-year basis. Research analysts forecast that Ralliant will post 2.37 EPS for the current fiscal year.

Ralliant Company Profile

Ralliant, Inc NYSE: RAL is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient's own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company's core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.